Asia Pacific Clinical Laboratory Services Market Size | Companies
The Asia Pacific clinical laboratory services market size was exhibited at USD 55.45 billion in 2023 and is projected to hit around USD 86.11 billion by 2033, growing at a CAGR of 4.5% during the forecast period 2024 to 2033.
| Report Coverage | Details |
| Market Size in 2024 | USD 57.95 Billion |
| Market Size by 2033 | USD 86.11 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 4.5% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Test Type, Service Provider, Application, Country |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | Japan, China, India, Australia, RoAP |
| Key Companies Profiled | Abbott Laboratories; ARUP Laboratories, Inc.; OPKO Health, Inc.; Bioscientia Healthcare GmbH; Charles River Laboratories International, Inc.; NeoGenomics Laboratories, Inc.; Healthscope Limited; Laboratory Corporation of America Holdings |
Market demand is expected to surge due to unmet medical needs, economic growth, and scientific advancements. A favorable regulatory environment in high-growth nations is attracting foreign investors, while government healthcare benefits, increased awareness, and a willingness to pay for quality care are driving market growth.
The Asia Pacific region accounted for 23.9% revenue share of the global clinical laboratory services market in 2023. The Asia-Pacific region is expected to experience rapid growth in the market due to several factors, including unmet medical needs, positive economic growth, and increasing scientific research.
The United Nations Fund for Population Activities predicts that the number of older people in the Asia-Pacific region will triple by 2050, reaching 1.3 billion individuals. Thailand, Japan, and China are experiencing a significant aging population driven by declining fertility rates and increasing life expectancies. This demographic shift is driving demand for clinical laboratory services in geriatric care, disease management, and health monitoring. Targeted healthcare policies and research funding are addressing health disparities faced by older women.
Geographic expansion strategies undertaken in the Asia Pacific market by major U.S.-based players to strengthen their position are anticipated to drive market growth further. This expansion will not only increase their market share but also enhance their capabilities to cater to the growing demand for clinical laboratory services in the region. For instance, in March 2024, Charles River Laboratories and the NUS Yong Loo Lin School of Medicine extended their gene therapy manufacturing alliance, providing high-quality plasmid DNA for engineered stem cells in cancer therapy.
In 2023, clinical chemistry tests dominated the market with a revenue share of over 60.0%, with its extensive range of tests analyzing body fluids like urine, plasma, and serum. These tests play a crucial role in diagnosis and are poised for increased demand due to rising life expectancy. The market is expected to grow as challenges in innovating tests for chronic diseases drive innovation; however, technological advances, POC testing, and alternative sampling methods are anticipated to help the market landscape further.
Medical microbiology and cytology tests are expected to experience the fastest CAGR of 9.5% over the forecast period. These tests diagnose and control diseases caused by nosocomial and infectious infections, driving regional demand further. Clinical microbiology laboratory services, including microbial culture analysis, are in high demand due to rising cases of contagious diseases.
In 2023, hospital-based laboratories dominated the market and are expected to retain dominance. This is driven by the high volume of patient tests conducted in hospitals, particularly for complex and severe disease conditions. The growing number of hospitals integrating laboratories into their premises and outreach programs is also contributing to the growth of this segment.
Clinic-based laboratories are expected to experience the fastest CAGR of 5.7% over the forecast period, driven by increasing demand for diagnostic testing, chronic disease prevalence, and lab equipment advancements. The adoption of Point-of-Care Testing (POCT) and integration of Laboratory Information Systems (LIS) with Electronic Health Records (EHRs) is enhancing workflow efficiency and data sharing, fueling the market’s growth.
In 2023, bioanalytical and laboratory chemistry services accounted for the largest application segment in terms of revenue share. In the Asia-Pacific region, these services utilize various techniques, including chromatography, mass spectrometry, and molecular biology, to meet diagnostic requirements. These services are crucial in drug development, concentration, and metabolite assessment. Providers employ validated methods to analyze biological samples for various applications.
The toxicology testing services segment is anticipated to exhibit rapid growth with a projected CAGR of 9.8% over the forecast period. More extensive laboratories prioritize turnaround time, requiring cost-benefit analyses. Pharmacogenetic testing helps predict adverse drug reactions, while therapeutic drug management optimizes drug doses. Furthermore, segment growth is aided by the growing pharmaceutical industry, increased government healthcare spending, and rising drug approvals and clinical trials.
China Clinical Laboratory Services Market Trends
The China clinical laboratory services market held the largest market share of 30.3% in the Asia Pacific region in 2023. This large share is driven by unmet medical needs, economic growth, and scientific advancements. A favorable regulatory environment attracting foreign investment, boosting demand, government healthcare initiatives, increased awareness, and a willingness to invest in quality healthcare are key drivers of growth in China.
Australia Clinical Laboratory Services Market Trends
The high burden of diseases in the country is expected to create growth opportunities in the clinical laboratory services market in Australia. The country is experiencing a growing prevalence of diseases, including diabetes, cardiovascular disorders, and other conditions. A notable example is atrial fibrillation, the most common type of irregular heartbeat, which affects over 500,000 people in Australia, according to the Baker Heart and Diabetes Institute.
Japan Clinical Laboratory Services Market Trends
The Japan clinical laboratory services market is expected to grow at a lucrative CAGR of 7.2% over the forecast period. This growth is driven by the demand for tests, a growing geriatric population, and increasing reimbursement rates. Over 50% of the market is hospital-based, and the country’s elderly population is susceptible to various diseases.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Asia Pacific clinical laboratory services market
Test Type
Service Provider
Application
Country
Chapter 1 Clinical Laboratory Services Market: Methodology And Scope
1.1 Market Segmentation
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
1.7 Global Market: Cagr Calculation
1.8 Global Market: Cagr Calculation
1.9 List Of Secondary Sources
1.10 Objectives
1.10.1 Objective 1:
1.10.2 Objective 2:
1.11 List Of Abbreviations
Chapter 2 Clinical Laboratory Services Market: Executive Summary
2.1 Clinical Laboratory Services Market: Market Outlook
2.1.1 Market Summary
Chapter 3 Clinical Laboratory Services Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Technological Advancements In The Filed Of Clinical Testing
3.3.1.2 Growing Prevalence Of Target Diseases Coupled With Rising Demand For Early Disease Diagnostic Tests
3.3.1.3 Introduction Of Novel Solutions
3.3.1.4 Introduction Of Home Health Tests
3.3.1.5 Outbreak Of Coivd-19 Technologies
3.3.2 Market Restraint Analysis
3.3.2.1 Presence Of Stringent Regulatory Framework
3.4 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.5 Industry Analysis - Porter’s
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances
3.7.1 New Product Launch
3.7.2 Acquisition
3.7.3 Expansion
3.7.4 Partnerships
3.7.5 Marketing & Promotions
Chapter 4. Clinical Laboratory Services Market: Test Type Estimates & Trend Analysis
4.1. Test Type Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. Global Clinical Laboratory Services Market by Test Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
4.4.1. Genetic Testing
4.4.1.1. Market estimates and forecasts, 2021 to 2033
4.4.2. Clinical Chemistry
4.4.2.1. Market estimates and forecasts, 2021 to 2033
4.4.2.2. Routine Chemistry Testing Market estimates and forecasts, 2021 to 2033
4.4.2.3. Therapeutic Drug Monitoring Testing Market estimates and forecasts, 2021 to 2033
4.4.2.4. Endocrinology Chemistry Testing Market estimates and forecasts, 2021 to 2033
4.4.2.5. Specialized Chemistry Testing Market estimates and forecasts, 2021 to 2033
4.4.2.6. Other Clinical Chemistry Testing Market estimates and forecasts, 2021 to 2033
4.4.3. Medical Microbiology Testing
4.4.3.1. Market estimates and forecasts, 2021 to 2033
4.4.3.2. Infectious Disease Testing Market estimates and forecasts, 2021 to 2033
4.4.3.3. Transplant Diagnostic Testing Market estimates and forecasts, 2021 to 2033
4.4.3.4. Other Microbiology Testing Market estimates and forecasts, 2021 to 2033
4.4.4. Hematology Testing
4.4.5. Immunology Testing
4.4.6. Cytology Testing
4.4.7. Drug of Abuse Testing
4.4.8. Other Esoteric Tests
4.4.8.1. Market estimates and forecasts, 2021 to 2033
Chapter 5. Clinical Laboratory Services Market: Service Provider Estimates & Trend Analysis
5.1. Service Provider Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. Global Clinical Laboratory Services Market by Service Provider Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.4.1. Hospital-Based Laboratories
5.4.1.1. Market estimates and forecasts, 2021 to 2033
5.4.2. Stand-Alone Laboratories
5.4.2.1. Market estimates and forecasts, 2021 to 2033
5.4.3. Clinic-Based Laboratories
5.4.3.1. Market estimates and forecasts, 2021 to 2033
Chapter 6. Clinical Laboratory Services Market: Application Estimates & Trend Analysis
6.1. Application Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. Global Clinical Laboratory Services Market by Application Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.4.1. Bioanalytical & Lab Chemistry Services
6.4.1.1. Market estimates and forecasts, 2021 to 2033
6.4.2. Toxicology Testing Services
6.4.2.1. Market estimates and forecasts, 2021 to 2033
6.4.3. Cell & Gene Therapy Related Services
6.4.3.1. Market estimates and forecasts, 2021 to 2033
6.4.4. Preclinical & Clinical Trial Related Services
6.4.4.1. Market estimates and forecasts, 2021 to 2033
6.4.5. Drug Discovery & Development Related Services
6.4.5.1. Market estimates and forecasts, 2021 to 2033
6.4.6. Others
6.4.6.1. Market estimates and forecasts, 2021 to 2033
Chapter 7. Clinical Laboratory Services Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. U.S. market estimates and forecasts, 2021 to 2033
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Canada market estimates and forecasts, 2021 to 2033
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. UK market estimates and forecasts, 2021 to 2033
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Germany market estimates and forecasts, 2021 to 2033
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. France market estimates and forecasts, 2021 to 2033
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Italy market estimates and forecasts, 2021 to 2033
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Spain market estimates and forecasts, 2021 to 2033
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Norway market estimates and forecasts, 2021 to 2033
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Sweden market estimates and forecasts, 2021 to 2033
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Denmark market estimates and forecasts, 2021 to 2033
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Japan market estimates and forecasts, 2021 to 2033
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. China market estimates and forecasts, 2021 to 2033
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. India market estimates and forecasts, 2021 to 2033
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Australia market estimates and forecasts, 2021 to 2033
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. South Korea market estimates and forecasts, 2021 to 2033
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Thailand market estimates and forecasts, 2021 to 2033
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Brazil market estimates and forecasts, 2021 to 2033
7.8.2. Mexico
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Mexico market estimates and forecasts, 2021 to 2033
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/ reimbursement structure
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts, 2021 to 2033
7.8.4. Colombia
7.8.4.1. Key country dynamics
7.8.4.2. Regulatory framework/ reimbursement structure
7.8.4.3. Competitive scenario
7.8.4.4. Colombia market estimates and forecasts, 2021 to 2033
7.8.5. Peru
7.8.5.1. Key country dynamics
7.8.5.2. Regulatory framework/ reimbursement structure
7.8.5.3. Competitive scenario
7.8.5.4. Peru market estimates and forecasts, 2021 to 2033
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. South Africa market estimates and forecasts, 2021 to 2033
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. UAE market estimates and forecasts, 2021 to 2033
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Kuwait market estimates and forecasts, 2021 to 2033
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP)
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. QIAGEN NV
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. QUEST DIAGNOSTICS INCORPORATED
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. OPKO HEALTH, INC
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. CHARLES RIVER LABORATORIES
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. ARUP LABORATORIES (ASSOCIATED REGIONAL AND UNIVERSITY PATHOLOGISTS, INC.)
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. SONIC HEALTHCARE
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. NEOGENOMICS LABORATORIES, INC.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. FRESENIUS MEDICAL CARE AG & CO. KGAA
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. SIEMENS HEALTHCARE LIMITED
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
8.3.14. SYNLAB International GmbH
8.3.14.1. Company overview
8.3.14.2. Financial performance
8.3.14.3. Product benchmarking
8.3.14.4. Strategic initiatives
8.3.15. Mayo Clinic Laboratories
8.3.15.1. Company overview
8.3.15.2. Financial performance
8.3.15.3. Product benchmarking
8.3.15.4. Strategic initiatives
8.3.16. Unilabs
8.3.16.1. Company overview
8.3.16.2. Financial performance
8.3.16.3. Product benchmarking
8.3.16.4. Strategic initiatives
8.3.17. Eurofins Scientific SE
8.3.17.1. Company overview
8.3.17.2. Financial performance
8.3.17.3. Product benchmarking
8.3.17.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers